RELAY, Ramucirumab Plus Erlotinib Versus Placebo Plus Erlotinib in Patients with Untreated, Epidermal Growth Factor Receptor Mutation-Positive, Metastatic Non-Small-Cell Lung Cancer: Safety Profile and Manageability
Journal
Drug Safety
Journal Volume
45
Journal Issue
1
Pages
45-64
Date Issued
2022
Author(s)
Nadal E.
Horinouchi H.
Nakagawa K.
Reck M.
Garon E.B.
Wei Y.-F.
Kollmeier J.
Frimodt-Moller B.
Barrett E.
Lipkovich O.
Visseren-Grul C.
Novello S.
Publisher
Adis
Type
journal article